Background : Oxidized low-density lipoprotein (oxLDL) is believed to play a key role in the development of atherosclerosis. However, the significance of anti-oxLDL antibodies (anti-oxLDL Ab) in atherogenesis is not yet clear. The purposes of this study were to assess whether anti-oxLDL Ab titers were related to other inflammatory markers of possible interest in atherosclerotic development, eg, soluble cell adhesion molecules, interleukin-6 (IL-6), and C-reactive protein (CRP) and to determine the prognostic value of anti-oxLDL Ab as a predictor of cardiac events in patients with unstable angina. Methods : Consecutive 60 patients (male 35, mean age 60 years) with unstable angina pectoris were included in this study. Blood samples were taken on admission, 24 and 72 hours after admission to assess the serum levels of anti-oxLDL Ab, cell adhesion molecules, IL-6, and CRP. Results : The levels of CRP and intercellular adhesion molecule-1 (ICAM-1) at 24 and 72 hours after admission were significantly higher than baseline levels of these (p<0.05, respectively) but not in other inflammatory markers. After adjusting for age, sex, body mass index, statin use, anti-platelets use, and homocysteine, anti-oxLDL Ab was positively correlated with CRP (r=0.72, p<0.001) and ICAM-1 (r=0.68, p<0.001). Elevated anti-oxLDL Ab (mean, >11.37 U/ml) and CRP levels (median, >2.4mg/L) on admission had a significantly lower 16 months event-free survival rate (Kaplan-Meier event free survival analysis, log rank p<0.01 and p<0.05, respectively). Multivariate analysis by logistic regression revealed that elevated levels of anti-oxLDL Ab (mean, >11.3U/ml) on admission were an independent risk factor of an adverse cardiac event (OR 2.2, 95% C.I 1.5-10.7, p=0.001). Conclusions : This study demonstrated that anti-oxLDL Ab was associated with CRP and adhesion molecule, especially ICAM-1, and can predict the likelihood of a cardiac events in patients with unstable angina. Elevated levels of anti-oxLDL Ab suggest plaque instability and may be useful for identification of patients with a higher risk of a cardiac event.